Bladder Cancer Breakthroughs: Insights from the NIAGARA Trial and Creatinine Cutoff Debate

A roundtable discussion on the muscle invasive blader cancer treatment landscape was moderated by Shilpa Gupta, MD, of Cleveland Clinic, and featured panelists Kala Sridhar, MD, MSc, FRCPC, of Princess Margaret Cancer Centre; Benjamin Garmezy, MD, of Sarah Cannon Research Institute; and Karine Tawagi, MD, of the University of Illinois. In part one, the panelists review the latest developments in bladder cancer treatment, with a focus on data presented at the 2024 European Society for Medical Oncology Congress, including the NIAGARA trial, which explored the efficacy of neoadjuvant chemotherapy in combination with immunotherapy for advanced bladder cancer.